NBE Therapeutics

Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race
Fierce Biotech
Thu, 12/10/20 - 11:27 am
Boehringer Ingelheim
NBE Therapeutics
M&A
Merck
antibody-drug conjugate
ROR1
Exelixis, NBE join forces for discovery and development of ADCs for cancer
Pharmaceutical Business Review
Wed, 09/9/20 - 10:32 am
Exelixis
NBE Therapeutics
antibody-drug conjugate
oncology